Loading organizations...

§ Private Profile · Belfast, United Kingdom
Neurovalens is a technology company.
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges. Their technology offers unparalleled activation of brainstem and hypothalamus nuclei, influencing autonomic function and circadian regulation.
Neurovalens has raised $34.1M across 7 funding rounds.
Neurovalens has raised $34.1M in total across 7 funding rounds.
Neurovalens has raised $34.1M across 7 funding rounds. Most recently, it raised $9.4M Debt / Other Equity in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 20, 2025 | $9.4M Debt Financing | Brian Cummings | ACF Investors, Innovation Ulster, IQ Capital, Whiterock Finance | Announced |
| Aug 1, 2025 | $7M Series U | — | ACF Investors | Announced |
| Apr 8, 2024 | $2.6M Series A Plus | — | — | Announced |
| Jul 20, 2020 | $6.4M Venture Round | Kerry Baldwin | Timothy Mills, Clarendon Fund Managers, Government, Jamie Andrews, Gaby Salem | Announced |
| Mar 1, 2019 | $6M Series A | Wharton Asset Management | ACF Investors, Beltrae Partners, IQ Capital, Jamie Andrews | Announced |
| Oct 17, 2017 | $1.6M Venture Round | — | — | Announced |
| Jul 1, 2017 | $1M Seed | — | ACF Investors, Beltrae Partners, Techstart Ventures | Announced |
Neurovalens has raised $34.1M in total across 7 funding rounds.
Neurovalens's investors include Brian Cummings, ACF Investors, Innovation Ulster, IQ Capital, Whiterock Finance, Kerry Baldwin, Timothy Mills, Clarendon Fund Managers, Government, Jamie Andrews, Gaby Salem, Wharton Asset Management.
Neurovalens is a Belfast-based health-tech company developing non-invasive neurostimulation devices to treat chronic conditions like insomnia, anxiety, and metabolic disorders without drugs or surgery.[1][3][6] Its flagship product, Modius Sleep, is an FDA-cleared headset that stimulates vestibular nerves behind the ears for 30 minutes nightly to regulate circadian rhythms and improve sleep in patients with chronic insomnia; it serves healthcare providers, veterans via VA programs, and individuals seeking drug-free solutions.[1][3][7][8] The company addresses massive unmet needs—such as 7 million U.S. adults with generalized anxiety and widespread chronic insomnia—through transdermal activation of brainstem and hypothalamus nuclei, with a product pipeline including Modius Anxiety and trials for PTSD, diabetes, and weight management; growth includes FDA clearances in 2023-2024, VA expansion in 2025, and scaling post-funding.[1][2][3][5]
Neurovalens emerged from the vision of co-founder Dr. Jason McKeown, a UK-trained MD PhD specializing in neuroscience and non-invasive neurostimulation, who combined his medical expertise with interests in electronics to tackle brain-related diseases without implants or pills.[2][7] Co-founded with Paul McGeoch around 2013-2015 in Belfast, UK, the idea stemmed from research at the University of California, San Diego, enabling skin-based stimulation of deep brain areas previously requiring surgery.[2][5][7] Early milestones included securing VC funding from IQ Capital to fund trials and regulatory hurdles, advancing to Phase 3 for diabetes/obesity, and achieving FDA 510(k) clearance for Modius Sleep in October 2023 after successful insomnia trials, followed by Modius Calm (anxiety) in March 2024.[3][5][7] Pivotal traction came via two FDA nods within five months, a team of ~20, and 2025 VA program access for U.S. veterans.[1][2]
Neurovalens rides the non-invasive neuromodulation wave, fueled by rising demand for drug-free mental health and metabolic treatments amid global epidemics of insomnia (affecting ~1/3 adults), anxiety, obesity, and diabetes.[2][5] Timing aligns with post-pandemic mental health crises, VA priorities for veterans, and FDA's faster medtech approvals, enabling home-use devices over invasive alternatives.[1][7] Market tailwinds include wellness-tech boom, insurance reimbursement potential, and transdermal tech advances reducing surgical risks; it influences ecosystems by pioneering VeNS for circadian/metabolic control, collaborating with UCSD, and scaling via Belfast's medtech hub to U.S./UK markets.[2][5][6]
Neurovalens is poised for explosive growth through U.S. insurance/NHS coverage, additional FDA nods for anxiety/PTSD/diabetes, and Modius expansions, potentially capturing shares in $100B+ sleep/anxiety markets.[2][3][5] Trends like AI-personalized neuromodulation and veteran-focused health policy will accelerate adoption, evolving its role from insomnia pioneer to metabolic disease leader. This drug-free innovator, born from a doctor's bold vision, could redefine early intervention in global health epidemics.[1][7]